Kick-Starting Molecular Theranostics in Renal Cell Carcinoma

Viktor Grünwald^{1

2}, Boris Hadschik³, Niklas Klümper^{4

5}, Ken Herrmann⁶

Affiliations

¹ Department for Urology, University Hospital Essen, Essen, Germany; viktor.gruenwald@uk-essen.de.
² Department for Medical Oncology, University Hospital Essen, Essen, Germany.
³ Department for Urology, University Hospital Essen, Essen, Germany.
⁴ Department for Urology, University Hospital Bonn, Bonn, Germany.
⁵ Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany; and.
⁶ Department for Nuclear Medicine, University Hospital Essen, Essen, Germany.

Free article

Comment

Viktor Grünwald et al. J Nucl Med. 2024.

Free article

. 2024 May 1;65(5):744-745.

doi: 10.2967/jnumed.124.267618.

Viktor Grünwald^{1

2}, Boris Hadschik³, Niklas Klümper^{4

5}, Ken Herrmann⁶

¹ Department for Urology, University Hospital Essen, Essen, Germany; viktor.gruenwald@uk-essen.de.
² Department for Medical Oncology, University Hospital Essen, Essen, Germany.
³ Department for Urology, University Hospital Essen, Essen, Germany.
⁴ Department for Urology, University Hospital Bonn, Bonn, Germany.
⁵ Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany; and.
⁶ Department for Nuclear Medicine, University Hospital Essen, Essen, Germany.

No abstract available

Comment on

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma.
Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, Haskali MB, Sparks RB, Vlasyuk O, Galetic I. Hofman MS, et al. J Nucl Med. 2024 Feb 22;65(5):740-3. doi: 10.2967/jnumed.123.267175. Online ahead of print. J Nucl Med. 2024. PMID: 38388517 Free PMC article.